Details for New Drug Application (NDA): 061895
✉ Email this page to a colleague
NDA 061895 describes ILOSONE, which is a drug marketed by Lilly and Dista and is included in seven NDAs. Additional details are available on the ILOSONE profile page.
The generic ingredient in ILOSONE is erythromycin estolate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin estolate; sulfisoxazole acetyl profile page.
The generic ingredient in ILOSONE is erythromycin estolate; sulfisoxazole acetyl. There are one hundred and three drug master file entries for this compound. Additional details are available on the erythromycin estolate; sulfisoxazole acetyl profile page.
Summary for 061895
| Tradename: | ILOSONE |
| Applicant: | Dista |
| Ingredient: | erythromycin estolate |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 061895
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, CHEWABLE;ORAL | Strength | EQ 125MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET, CHEWABLE;ORAL | Strength | EQ 250MG BASE | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
